######### Bovine Spongiform Encephalopathy #########
Greetings List members,
thought i would pass this about vaccineCJD. But i would be curious
to know, how many times has this happened? How many documented
cases of this type transmission of a TSE with animals? The
scrapie agent has been the one used most, to study CJD. Why
could it not be, that the "V" in vCJD, mean vaccineCJD?
It could explain the children and CJD. With the deaths of these
young people, has anyone looked at their vaccination records?
just a thought???
Terry S. Singeltary SR., Bacliff, Texas USA
There has been one instance of inadvertant [sic] transmission of the
scrapie agent to sheep through louping ill vaccine (Gordon, Bronlee and
Wilson 1939). One of the three batches of vaccine made in 1935 at the
Moredun Institute contained the scrapie agent resulting in 7% of the
recipients of the 18, 000 doses in the batch developing scrapie. This
vaccine was made from formalin-inactivated sheep brain, and brought to
the attention of research workers that formalin, at a concentration of
0.35% for at least 3 months, which inactivated conventional viruses, did
not totally inactivate the scrapie agent.
4. Questions we might want to have answered are:
the highest risk would be from parenterals prepared from brain (eg
rabies vaccine). Any species in which transmissible spongiform
encephalopathies have been described would be suspect (natural
infections in sheep, goats, cattle, deer, mink, but can be transmitted
to hamster, mouse, guinea-pig etc). Are sterilisation processes
adequate for the most resistant strain of scrapie agent or for CJD
agent? Should companies be asked to include investigation for inclusion
of scrapie agent (eg mouse innoculation [sic]) in at least some batches?
If BSE behaves like scrapie, then we might expect other nervous tissue,
spleen, lymph nodes and placenta to be contaminated. Infection has been
described in other tissues too, eg gut wall, and we can not [sic] be
sure blood is free. Do we know what bovine materials are used in which
products, both as the active ingredient and in production? Bovine active
ingredients in human products include insulin, vasopressin, bone, immune
globulins, fibrin, dermal collagen, albumin. Bovine serum albumin and
fetal calf serum must be used in preparation of very many products. For
each of these products would any BSE agent be destroyed or eliminated
in processing? If not, and the product is administered parenterally or
topically into an open wound, might there be a risk? [For oral
products, there would only be a trivially increased load on top of that
taken in food in omnivores/carnivores including man. But for some
herbivores, this might allow the agent to be introduced into yet another
Medicines and medical devises;
and they are still asking the same damn questions, over and over
again. This was 2 June 1988. we must act soon, or forget it, the hope
of eradicating human TSE's will be out the door.
Terry S. Singeltary Sr., Bacliff, Texas USA
"Terry S. Singeltary Sr." wrote:
> ######### Bovine Spongiform Encephalopathy
> Greetings list members,
> this document is very disturbing, considering if they continued to use
> these vaccines, the U.K. could loose a generation of children. If they
> continue to force these vaccines on children, they could loose more than
> just one generation, looking at the inventory. I did not know, that a
> Government body or bodies, if you include the United States, could be
> so stupid to this disease, with the evidence they have to date.
> It's as blatant and negligent as you can get. You may think the BSE
> Inquiry is almost over, but that was only the beginning.
> The Truth Will Come...
> (just hope i'm alive to see it)
> kind regards,
> Terry S. Singeltary Sr., Bacliff, Texas USA
> BSE3/1 0250
> Dr Harris (MED)
> From: Dr Adams (MB3B)
> cc - Dr. Pickles
> Date: 14 February 1989
> BOVINE SPONGIFORM ENCEPHALOPATHY
> This minute details the information received on human vaccines in
> response to telephone enquires, and details of forthcoming expert
> group meetings during February 1989.
> We have contacted all the major vaccine product licence holders whose
> products are likely to be used in children. Many manufacturers use
> bovine material. As can be seen, this information is diverse and
> incomplete. Each company stressed that they could not give an accurate
> assessment without detailed researches, given the complexity of
> sourcing/purchasing arrangements.
> All the licences are detailed in appendix 1; the overview is as follows;
> 1. XXXXXXXXXXX have polio, measles, mumps, rubella, rotavirus vaccines.
> AlL use bovine serum from a UK source and bovine commercial product from
> unknown source. Some agent comes from the USA and New Zealand.
> 2. XXXXXXXXXXX (see Appendix 2). All their vaccines apart from yellow
> fever, cholera and typhoid contain bovine material:
> --Oral polio; up to 1988, foetal calf serum was used from UK and New
> Zealand (pooled); since 1988 foetal calf serum only from New Zealand.
> Large stocks are held.
> --Rubella; bulk was made before 1979 from foetal calf serum from UK
> and New Zealand. None has been made as there are some 15 years stock.
> --Diphtheria; UK bovine beef muscle and ox heart is used but since the
> end of 1988 this has been sourced from Eire. There are 1,250 litres
> of stock.
> --Tetanus; this involves bovine material from the UK mainly Scottish.
> There are 21,000 litres of stock.
> --Pertussis; uses bovine material from the UK. There are 63,000 litres
> of stock.
> --They consider that to switch to a non-UK source will take a minimum
> of 6-18 months and to switch to a non-bovine source will take a minimum
> of five years.
> 3. XXXXXXXXXXX have measles, mumps, MMR, rubella vaccines. These are
> sourced from the USA and the company believes that US material only is
> BSE3/1 0251
> 4. XXXXXXXXXXX have a measles vaccine using bovine serum from the UK.
> there are 440,000 units of stock.
> --They have also got MMR using bovine serum from the UK.
> 5. XXXXXXXXXXX have influenza, rubella, measles, MMR vaccines likely to
> be used in children. Of those they think that only MMR contains bovine
> material which is probably a French origin.
> 6. XXXXXXXXXXX have diphtheria/tetanus and potasses on clinical trial.
> These use veal material, some of which has come from the UK and has
> been made by XXXXXXXXXXX (see above).
> 7. XXXXXXXXXXX have influenza vaccines which are made up in egg medium.
> 8. XXXXXXXXXXX The Secretary of State has a number of licences. We
> understand that the inactivated polio vaccine is no longer being used.
> There is a stock of smallpox vaccine. We have not been able to determine
> the source material. (Made in sheep very unlikely to certain bovine
> 9. XXXXXXXXXXX have acellular triple vaccine in which material of
> UK bovine source has been used.
> As far as I can see, XXXXXXXXXXX are the sole supplier of pertussis
> vaccine which uses bovine casein digest.
> You should also be aware that DH has made arrangements for meningococal
> vaccine to be available, on a named patient basis, from
> XXXXXXXXXXX and XXXXXXXXXXX. Both companies use bovine media in
> Expert Group Meetings
> The Veterinary Products Conmmittee will discuss the proposed draft
> guidelines and significance thereof to veterinary vaccine products
> at 2.00pm on Thursday 16 February 1989 with professor Armo in the
> Chair. (See appendix for VPC Committee constitution).
> The Human & Veterinary Medicines Working Group re BSE will meet on
> 22 February at 10.00am Market Towers. The meeting will be to provide
> expert information to CSM on the 23 February in the light of the
> Southwood report and concerns about vaccines. In addition to Department
> of Health and MAFF officials, Professor Collee, Dr Schild, Dr Minor,
> Dr Tyrell from the Biologicals Subcommittee will be present,
> Dr Kimberlin and Dr Martin and Mr Wilesmith have been invited.
> Professor Collee will be in the Chair.
> The Committee on Safety of Medicines will meet on the 23 February. They
> will consider advice from the working group, draft guidelines for the
> industry, a draft letter to product licence holders of human medicines,
> and recommendations regarding priority actions on particular product
> MAFF briefing note is added at Appendix 6.
> DR P N ADAMS